Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

NCT05079360 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Decided to halt and will potentially reopen in the future.

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Sabizabulin
DRUG: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator

Sponsor

Veru Inc.